Founder mutations are an important cause of Lynch syndrome and facilitate genetic testing in specific ethnic populations. Two putative founder mutations in MSH6 were analyzed in 2685 colorectal cancer (CRC) cases, 337 endometrial cancer (EnCa) cases and 3310 healthy controls of Ashkenazi Jewish (AJ) descent from population-based and hospital-based case-control studies in Israel, Canada and the United States. The carriers were haplotyped and the age of the mutations was estimated. MSH6 *c.3984_3987dupGTCA was found in 8/2685 CRC cases, 2/337 EnCa cases, and 1/3310 controls, consistent with a high risk of CRC (odds ratio (OR) = 9.9, 95% confidence interval (CI) = 1.2-78.9, p = 0.0079) and a very high risk of EnCa (OR = 19.6, 95% CI = 1.8-217.2, p = 0.0006). MSH6 *c.3959_3962delCAAG was identified in 3/2685 CRC cases, 2/337 EnCa cases and no controls. Each mutation was observed on separate conserved haplotypes. MSH6 *c.3984_3987dupGTCA and MSH6 *c.3959_3962delCAAG probably arose around 585 CE and 685 CE, respectively. No carriers were identified in Sephardi Jews (450 cases and 490 controls). Truncating mutations MSH6 *c.3984_3987dupGTCA and MSH6 *c.3959_3962delCAAG cause Lynch syndrome and are founder mutations in Ashkenazi Jews. Together with other AJ founder mutations, they contribute substantially to the incidence of CRC and EnCa and are important tools for the early diagnosis and appropriate management of AJ Lynch syndrome patients.
Lynch syndrome is the most common autosomal dominant condition pre-disposing to colorectal cancer (CRC). It is characterized by early onset cancers of the colorectum, endometrium, small bowel, ureter and renal pelvis (1) , as well as other malignancies (2) . Lynch syndrome is caused by germline mutations in mismatch-repair (MMR) genes, the common of which occur in MLH1 (3) and MSH2 (4) , and are less frequently seen in MSH6 (5, 6) and PMS2 (7) .
The MSH6 gene is localized at chromosome 2p15-16 and consists of 10 exons encoding a 1360 amino acid protein. The MSH6 protein interacts with the MSH2 protein to form the MutSα heterodimer (5) . The primary function of MutSα is to initiate the repair process by binding to DNA mismatches detected by MSH6. The characteristic role of this heterodimer is to correct single mispaired bases or small insertion or deletion loops (8) . Most reports indicate an attenuated phenotype of MSH6 -related Lynch syndrome in comparison with mutations of MLH1 or MSH2 genes. Although fewer families with MSH6 mutations fulfill the Amsterdam criteria than families with either MLH1 or MSH2 mutations, the characteristic features of MSH6 mutation families comprise a higher risk for CRC, endometrial, ovarian, upper urinary tract, and stomach cancers (9) . Moreover, families with MSH6 mutations have a higher incidence of extracolonic cancers in comparison with other Lynch families (10) .
Several studies have investigated the frequency of MSH6 mutations in CRCs and endometrial cancers (EnCas). About 10% of Lynch syndrome CRCs and 0.3% of all CRCs are explained by the mutations in MSH6 (11, 12) . The prevalence of MSH6 mutations in EnCa patients who were not selected for family history is about 1.1% (13) . A recent study of 113 MSH6 families estimated cumulative risks to age 80 years for CRC to be 44% for men and 20% for women; for EnCa, the risk was 44%. MSH6 mutation carriers had an 8-fold increased incidence of CRC in comparison with incidence in general population, and women with MSH6 mutations had a 26-fold increased incidence of EnCa (14) . In families with MSH6 mutations, the onset of CRC and EnCa is significantly delayed compared to families with MLH1 or MSH2 mutations (MSH6 vs MSH2 /MLH1 = 55 years vs 44/41 years for CRC and 55 years vs 49/48 years for EnCa) (15) .
Over 500 unique variants have been identified in MSH6 gene (16) . Two recently described mutations in MSH6 exon 9 are truncating mutations identified in several families around the world: the mutation c.3959_3962delCAAG (rs63751151) (p.Ala1320GlufsX6) was first reported in an EnCa patient of unknown ethnicity from the United States, where her MSI-positive tumor with an unmethylated MLH1 promoter was diagnosed at the age 71 (17) and the mutation c.3984_3987dupGTCA (p.Leu1330ValfsX12) was first reported to occur in an Ashkenazi Jewish (AJ) family with a history of CRCs and adenomatous polyps (18) , and using slightly different nomenclature was later reported in two families; one from the Netherlands (9) and another family from the United States (19) . A recently published Israeli study found c.3984_3987dupGTCA in 19 members of four AJ families (20) .
The aim of the present study was to characterize the MSH6 mutations c.3984_3987dupGTCA (referred below as MSH6 *dup) and c.3959_3962 delCAAG (referred below as MSH6 *del) and estimate the magnitude of the contribution of these mutations to the Lynch syndrome in the AJ population. The frequency of these mutations was evaluated in a large, population-based case-control study in northern Israel and in series of AJ individuals with colorectal, endometrial, or ovarian cancer, ascertained in North America. Furthermore, we sought to establish whether these two mutations are founder mutations and to calculate the age of these mutations in the AJ population.
Materials and methods

Study samples
The present study included individuals of AJ descent from centers in Israel, Canada, and the United States. We studied the frequency of these two mutations in several different types of datasets: (i) population-based series of cases and controls (Israel); (ii) individuals with a personal and/or family history of CRCs and other Lynch syndromeassociated tumors referred to high-risk clinics (Montreal); (iii) familial gastro-intestinal cancer registry-based cases (Toronto); (iv) hospitalbased series of EnCa cases and controls (New York); (v) unaffected control individuals (Montreal and Toronto) and (vi) carriers identified through a CLIA-certified commercial laboratory (Mayo clinic). These datasets are described briefly below. 
Clinical laboratory series
Two carriers of MSH6* dup mutation were identified in the Mayo Medical Laboratory mutation database. These carriers were invited to participate in this research through the University of Michigan Cancer Genetics Registry. The patients signed written, informed consent and donated additional blood samples for haplotype analysis.
Genotyping of MSH6 exon 9 and haplotype analysis Methods for screening of MSH6 exon 9 for deletions and duplications varied between different centers, but all carriers were re-analyzed and haplotyped at the University of Michigan. DNA fragments containing exon 9 and microsatellite markers were amplified using PCR. PCR product size was determined by fragment length analysis using ABI3730 instrument (Applied Biosystems, Foster City, CA) and compared to the positive control carrying MSH6 *dup and negative control (tested by sequencing) using GeneMarker (State College, PA) software. Samples with the fragment size different from expected 164 base pairs were sequenced using the same set of primers from both sides. Single nucleotide polymorphisms (SNPs) were analyzed by direct sequencing. Primers and reaction conditions are described in Supplementary  Table S1 .
Microsatellite instability analysis and immunohistochemistry
Microsatellite instability assays were performed as described elsewhere (21) using microdissected DNA from paraffin-embedded tissue blocks. Five markers (BAT25, BAT26, D2S123, D5S346, and D17S250, often called the Bethesda panel) were PCR amplified using radioactively labeled primers. The patterns of the microsatellite markers in normal tissue and tumor were compared to find changes in marker length. Samples were categorized according to established criteria (7): MSI-High (two or more markers are unstable), MSI-Low (one marker is unstable), microsatellite stable (MSS) ( no markers being unstable). Tumor samples from MSH6 exon 9 mutation carriers were retrieved and tested for the expression of MLH1, MSH2, MSH6 and PMS2 proteins. Immunohistochemistry (IHC) was performed on 4-μm sections of formalin-fixed and paraffin-embedded tissues. Sections were dried, de-paraffinized and re-hydrated. Slides were stained with monoclonal antibodies. The protein expression in normal lymphocytes and colonocytes adjacent to the tumor served as an internal positive control.
Statistical analysis
The association between MSH6 mutations and risk of CRC and EnCa was estimated using Fisher's exact test at SAS 9.1 (The SAS Institute, Cary, NC). Haplotype reconstruction was performed using PHASE v.2.1.1 (22, 23) . Uncertain genotype phases in haplotype estimates were excluded from the analysis. The age of the mutation was estimated using a Bayesian MCMC linkage disequilibrium mapping approach (DMLE+ software) (24) . Genetic distance was estimated at 1 Mb corresponding to 1 cM. We assumed population growth rate 1.125-fold per generation, considering the population of Jewish people in a northeastern European region of 11,000 in the year 600 and 5 million in the year 1900. Considering a lifetime risk of CRC of 6.85%, a worldwide population of Ashkenazi Jews of 13 million (25) , and the mutation prevalence among CRC cases of 0.3% (duplication) and 0.1% (deletion) estimated from the MECC study, we calculated the number of disease chromosomes in AJ population: 2672 for duplication and 891 for deletion. Accordingly, the proportion of mutation carrying chromosomes sampled was 0.00299 (8/2672) and 0.00337 (3/891) for duplication and deletion, respectively.
Results
Identification and screening for MSH6 exon 9 indel mutations
An AJ family found to carry MSH6 *dup was evaluated at McGill University for Lynch syndrome. Based on this case and prior reports of this mutation in the literature, we hypothesized that this variant might represent a founder mutation identifiable among Ashkenazi Jews. This led to a comprehensive search among investigators with large series of AJ CRC cases, EnCa cases, and controls. One further family from Montreal, one family from Toronto, eight families from northern Israel, and two families from MSKCC were found to carry the same mutation. One family ascertained through Mayo Medical Labs with MSH6 *dup mutation was also ascertained. As the mutation screening relied on fragment size analysis of PCR products, a second mutation within the same region was also recognized corresponding to a truncating mutation, MSH6 *del in three families from northern Israel, three families from Toronto, and two families from MSKCC ( Table 1) .
Frequency of MSH6 exon 9 dup-del mutations in Ashkenazi Jews and risk of CRC We evaluated the frequency of MSH6 *dup and MSH6 *del mutations in the MECC study with the addition of control AJ individuals from multiple centers in Israel, Canada, and the United States. MSH6 *dup was found in 8 of 2685 (0.3%) cases and 1 of 3310 (0.03%) controls. The only control carrying MSH6 *dup had an EnCa at age 61 and developed cecal cancer at age 76, several years after being ascertained as a control without CRC. Considering this fact and epidemiologic principles (26), we included this carrier to both case and control groups to calculate the odds ratio (OR). To evaluate the risk of CRC associated with these two MSH6 mutations, we used MECC cases (n = 2685) and controls (n = 1591) as well as large series of healthy Ashkenazi Jews from a study carried out at Women's College Research Institute, Toronto (n = 1011), MSKCC, New York (n = 285) and JGH, Montreal (n = 423). The carriers of MSH6 had a very high risk of CRC (OR = 9.9, 95% confidence interval (CI) = 1.2-78.6, p = 0.0079) ( Table 2 ). The MSH6 *del was less common, identified in 3 of 2685 (0.11%) cases and no controls. No carriers of either mutation were identified in 450 Sephardi Jewish cases or 490 Sephardi Jewish controls from Israel.
MSH6*dup and MSH6*del mutations in patients and controls from hospital-based series
At the JGH, Montreal, one of the 22 (4.5%) CRC affected probands from high-risk CRC families carried MSH6 *dup, and there were no MSH6 *del mutations found.
One carrier of MSH6 *dup and three carriers of MSH6 *del were identified in 490 AJ patients from Toronto registry. After testing family members of the identified carriers, two carriers of MSH6 *dup (family 11) and four MSH6 *del carriers (families 16 and 17) were detected (Figs 1 and 2) . In 337 hospital-based cases of AJ patients with EnCa from MSKCC, two carriers (0.6%) of MSH6 *dup and two carriers (0.6%) of MSH6 *del mutations were identified. Roughly estimated, the risk of EnCa in AJ MSH6 *dup mutation carriers is high (OR = 19.6, 95%CI = 1.8-217.2, p = 0.0006) ( Table 2) . Both affected twins from Mayo clinic were diagnosed with sebaceous adenoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC), but did not have any Lynch syndromeassociated cancers. In one of the brothers, IHC analysis of sebaceous adenoma showed impaired expression of MSH6 protein. Testing for mutations in exon 9 in MSH6 showed MSH6* dup in both brothers.
Clinicopathological features of MSH6 founder mutation carriers
Among all carriers the mean age at diagnosis of CRC was 66 years (median 67 years), and the mean age at diagnosis of EnCa was 54 years (median 52 years). Microsatellite instability and IHC staining against mismatch-repair (MMR) proteins were performed in carriers with available tumor tissue ( Table 1) . MSI status of the tumors was determined for 37% of carriers (10/27) and IHC was available for three CRCs, three endometrial tumors, and one sebaceous adenoma. In our data, 33% (3/10) of carriers had MSS tumors and 67% (7/10) had MSI-High tumors. It is noteworthy that three out of seven MSI-High tumors were unstable in mononucleotide markers only. In six out of seven tumors with IHC, the MSH6 protein was not expressed, while other MMR proteins were intact (MSH2, MLH1, PMS2).
Characteristics of MSH6 mutation-positive families
A total of 19 MSH6 *dup carriers and 12 MSH6 *del carriers from 22 unrelated families were identified (Table 3 , Figs 1 and 2) . Among all carriers, 18 MSH6 *dup carriers and 8 MSH6 *del carriers were affected with CRC or EnCa ( Table 1) . None of the families met Amsterdam criteria I and only two families met Amsterdam criteria II (families 7 and 18). Although families did not fulfill Amsterdam criteria, the family history of cancer is suggestive of mutations in the MMR genes. In family 11, both mother (I.2) and daughter (II.4) had CRC, while the daughter was diagnosed at the age of 50 followed by the diagnosis of EnCa in a year. In families 16 and 17, the patients (I.1 and I.1) had two synchronous colorectal tumors; the proband in the family 7 and the patient I.2 from family 2 were diagnosed with metachronous CRC. It is noteworthy that three MSH6*dup carriers had SCC and BCC.
Haplotype analysis
To characterize the haplotypes associated with MSH6 exon 9 deletion and duplication we analyzed four microsatellite markers (AtnACAGn, CAn, D2S1352, D2S123) and four SNPs (rs1800 932, rs1800935, c.1146+14A>T, rs3136367) in all identified carriers ( Table 3 ). The markers cover about 3.4 Mb including MSH6 sequence. The marker AtnACAGn is approximately 144 kb upstream of MSH6, followed by SNPs in the coding region of MSH6, two polymorphic microsatellite loci (CAn, D2S1352), with the last marker D2S123 located 32 Mb away from the 3 -UTR of the MSH6. The physical order of the markers is tel -AtnACAGn -rs1800932 -rs1800935 -c.1146+14A>T -rs3136367 -CAn -D2S1352 -D2S123 -cen. Haplotype analysis showed separate conserved haplotypes for each mutation. The haplotype tel-163-G-C-T-G-MSH6 *dup-179-113-225-cen was observed with MSH6 exon 9 dup in 16/19 carriers. Three MSH6 *dup carriers had recombination events involving the markers at the ends of the haplotype (AtnACAGn, D2S1352, D2S123). The MSH6 *del was associated with the haplotype tel-151-A-T-T-G-MSH6 *del-175-110-210-cen found in 8/12 carriers. Four MSH6 *del carriers had recombination events involving the marker D2S1352.
Age of MSH6 exon 9 indel mutations
We estimated the age of MSH6 *dup and MSH6 *del using an established method of combined markers that utilizes rate of recombination and population frequency of flanking marker alleles (24 The case-control settings of the MECC study allowed us to estimate frequency and CRC related risk of MSH6 *dup and MSH6 *del in Ashkenazi and Sephardi Jews. MSH6 *dup was found in 0.3% and MSH6 *del in 0.1% of Ashkenazi Jews with CRC, and was not observed in 940 Sephardi Jewish cases and controls. We identified one MSH6 *dup carrier among the MECC controls, who developed CRC after being ascertained as a control. This carrier was included in the analysis both as a control and a case. Our data indicate that carriers of MSH6 *dup have an almost 10 times higher risk to develop CRC than do non-carriers (OR = 9.9, 95% CI = 1.2-78.9, p = 0.0079). The frequency of Lynch syndrome among unselected CRC cases is ∼3-5%, which corresponds to 81-134 cases of Lynch syndrome in the 2685 MECC CRC cases. Therefore, although the combined frequency of MSH6 *dup and MSH6 *del mutations is only 0.4% in CRC patients of AJ origin, the frequency of these mutations in AJ patients with Lynch syndrome is probably 8-14% (11 of 81-134 cases). EnCa risk, roughly estimated from the hospital-based series, was about 20 times higher in the carriers of MSH6 *dup than in non-carriers (OR = 19.6, 95% CI = 1.8-217.2, p = 0.0006). We used the only identified AJ control carrying MSH6 *dup from the MECC study for approximate calculation of the risk of EnCa, although this patient had an EnCa before being ascertained as a control. Despite the wide CIs, the point estimates of the risk of CRC and EnCa in our study are, however, very comparable to the risk showed in the recent analysis of 113 families with MSH6 mutations (14) . This study found an 8-fold increase in risk of CRC and 26-fold increase in risk of EnCa. In addition, the fact that we only observed one carrier in 3310 controls, and this person later developed a Lynch-related cancer is supportive of our conjecture that these are highly penetrant alleles.
In our data, the mean age at diagnosis of CRC among carriers of MSH6 exon 9 mutations was 66 years, 20 years older than in carriers of MSH2 or MLH1 mutations (44 years) (10). The mean age at diagnosis of EnCa was 54 years, comparable with previous studies (9) . This later age of onset may explain the fact that only two families meet Amsterdam criteria in our data.
About half of the MSI-High tumors (3/7) were instable in mononucleotide markers only (BAT25, BAT26, beta-catenin) in line with previous observations that mononucleotide microsatellite markers are more frequently affected in tumors harboring MSH6 germline mutations (27) .
Recombination events allowed estimation of the age of the mutations. MSH6 *dup arose ∼1425 years ago in the sixth century CE, and MSH6 *del arose ∼1325 years ago in the seventh century CE, both at the time of formation of the AJ ethnicity in Western Europe. These mutations are much older than other previously described Ashkenazi founder mutations in MMR genes, such as MSH2 c.1906G>C, that probably arose in 15th-18th century CE, but more recent than BRCA2 c.5946delT (traditionally known as 6174delT, 3rd century BCE) and APC p.I1307K (7th century BCE) (28) . The estimated age of the founder mutations can in part explain their frequency in Ashkenazi Jews, more recent mutations (MSH6 *dup, MSH6 *del) have lower than 0.03% frequency in general population, while the older mutations (BRCA2 c.5946delT and APC p.I1307K) have much higher frequency of 1.5% and 6%, respectively (29, 30) .
Only a few AJ founder mutations leading to CRC and EnCa have been described until now. In addition to the MSH6 exon 9 deletion and duplication characterized here, previous studies report another MMR gene mutation, MSH2 *c.1906G>C (common name A636P), associated with increased risk of both CRC (31) and EnCa (31, 32) , as well as mutations in APC *c.3920T>A (common name I1307K) (30) and BLM *c.2207_2212delATCTGA insTAGATTC (common name BLM Ash ) (33) associated with increased risk of CRC only. The reported frequency of APC *I1307K, BLM Ash and MSH2 *A636P among AJ CRC patients is 12% (34), 1-3% (33), and 1% (31), respectively. The frequency of MSH2 *A636P in AJ EnCa patients is also about 1% (31) . Altogether AJ founder mutations (APC *I1307K, BLM Ash , MSH2 *A636P, MSH6 *dup, and MSH6 *del) are associated with approximately 14-16% of all CRC cases and 2.2% of all EnCa cases in Ashkenazi Jews. The frequency of these mutations in AJ patients with family history of CRC and/or EnCa can be significantly higher. A panel designed to detect known AJ founder mutations consisting of APC *I1307K, BLM Ash , MSH2 *A636P, MSH6 *dup, and MSH6 *del could have value as a first-line screen in all AJ CRC and/or EnCa cases, irrespective of family history, IHC or MSI status.
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